Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Current treatment of choice for chronic hepatitis C infection.

Yasin T, Riley TR, Schreibman IR.

Infect Drug Resist. 2011;4:11-8. doi: 10.2147/IDR.S4827. Epub 2011 Jan 12.

2.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
3.

Protease inhibitors for hepatitis C: economic implications.

Turner SJ, Brown J, Paladino JA.

Pharmacoeconomics. 2013 Sep;31(9):739-51. doi: 10.1007/s40273-013-0073-2. Review.

PMID:
23839698
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

5.

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response.

Chak E, Saab S.

Curr Hepat Rep. 2010 Aug;9(3):147-154. Epub 2010 Jun 19.

6.

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 Jun 17;(6):CD011132. doi: 10.1002/14651858.CD011132.pub2. Review.

PMID:
24937404
7.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
8.

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.

Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y.

BMC Res Notes. 2012 Mar 10;5:135. doi: 10.1186/1756-0500-5-135.

9.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

10.

Current and future treatment of hepatitis C.

Manns MP, Cornberg M, Wedemeyer H.

Indian J Gastroenterol. 2001 Mar;20 Suppl 1:C47-51. Review.

PMID:
11293180
11.

Review article: novel therapeutic options for chronic hepatitis C.

Cholongitas E, Papatheodoridis GV.

Aliment Pharmacol Ther. 2008 May;27(10):866-84. doi: 10.1111/j.1365-2036.2008.03644.x. Epub 2008 Feb 12. Review.

12.

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Garnock-Jones KP.

Drugs. 2012 Dec 24;72(18):2431-56. doi: 10.2165/11209560-000000000-00000. Review.

PMID:
23231027
13.

[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].

Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Rókusz L, Szalay F, Telegdy L, Tornai I, Werling K, Makara M.

Orv Hetil. 2015 Mar 1;156(9):343-51. doi: 10.1556/OH.2015.30106. Review. Hungarian.

PMID:
25702254
14.

[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].

Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I.

Orv Hetil. 2014 Mar;155 Suppl:3-24. doi: 10.1556/OH.2013.29893. Hungarian.

PMID:
24631886
15.

Peginterferon-alpha(2b) and ribavirin.

Ahn J, Flamm S.

Expert Rev Anti Infect Ther. 2004 Feb;2(1):17-25. Review.

PMID:
15482168
16.
17.

Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.

Baker RD, Dee D, Baker SS.

J Clin Gastroenterol. 2007 Jan;41(1):111-4.

PMID:
17198073
18.

Chronic hepatitis C virus infection in renal transplant: treatment and outcome.

Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.

Clin Transplant. 2006 Nov-Dec;20(6):677-83.

PMID:
17100715
19.
20.

Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.

Emara MH, El-Gammal NE, Mohamed LA, Bahgat MM.

Virol J. 2010 Nov 17;7:324. doi: 10.1186/1743-422X-7-324.

Supplemental Content

Support Center